Lilly reshuffles its diabetes and obesity leadership weeks before the Zepbound decision

Eli Lilly announced a round of leadership changes on Oct. 4, 2023, replacing the executive who guided Mounjaro through its diabetes launch just weeks before U.S. regulators were expected to decide whether the same drug, tirzepatide, could be sold for weight loss ^[1][2].

Mike Mason, who led Lilly's diabetes and obesity unit for four years and had spent 34 years at the company, is retiring at the end of 2023 ^[2]. He will be replaced starting Jan. 1 by Patrik Jonsson, a 33-year Lilly veteran who most recently ran the company's immunology business and served as president of Lilly USA ^[1][2]. In his new role, Jonsson will oversee Lilly's marketed diabetes and obesity products along with drugs still in development, including tirzepatide, the experimental obesity drug retatrutide, and the obesity pill orforglipron ^[1].

The timing mattered. The changes landed just before the Food and Drug Administration's decision on whether to approve tirzepatide, then sold as Mounjaro for diabetes, as a treatment for obesity ^[1][2]. That drug went on to reach the market under the brand name Zepbound. At the time of the announcement, Mounjaro sales had already reached $979.7 million in the most recent quarter, and GLP-1 drugs as a class were projected to create a market worth an estimated $100 billion within a decade ^[1].

The reshuffle went beyond the diabetes and obesity unit. Chief scientific officer Daniel Skovronsky picked up responsibility for Lilly's immunology division, a job Jonsson had held ^[1][2]. Jennifer Oleksiw moved into the chief customer officer role Jonsson vacated ^[2]. In oncology, chief medical officer David Hyman took on a company-wide medical role, and Mark Genovese, arriving from Gilead Sciences and previously on the faculty at Stanford, took charge of mid- and late-stage inflammation drug development ^[2]. Lilly CEO David Ricks credited Mason with an "enduring legacy" reflecting "his deep passion for patients" ^[2].

Why it matters for patients

Executive turnover at a drugmaker does not change a medication's ingredients, dosing, or safety profile. But it can signal how a company plans to run the business behind a drug that patients rely on. Lilly was preparing to launch tirzepatide for obesity into a market it expected to grow enormously, and it put someone with broad experience across immunology and U.S. operations in charge of that expansion rather than the executive who had built the diabetes side of the business ^[1][2].

For people using Mounjaro or waiting on the obesity version, the leadership change is mostly background noise. What matters more directly is what the FDA decides about approval, dosing, and labeling, and what Lilly does with pricing, supply, and manufacturing as the cardiometabolic unit's mandate grows to include not just tirzepatide but next-generation candidates like retatrutide and orforglipron ^[1]. Sources reviewed for this story do not say whether the leadership change affected supply, pricing, or the approval timeline itself.

What happens next

Jonsson's expanded role took effect Jan. 1, 2024 ^[1][2]. The FDA's decision on tirzepatide for obesity, which the sources describe as imminent at the time of this announcement, was the next milestone investors and patients were watching, though the exact approval date is not stated in these sources ^[1][2]. Lilly's own reporting at the time showed $29 billion in 2022 sales and $15 billion in sales through the first half of 2023, giving a sense of the scale of the business Jonsson was taking over ^[2].